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Purpose of review
Cognitive impairment is associated with negative effects on solid organ transplant candidates, recipients,
and their care partners. However, because of the heterogeneity of mechanisms, presentations, and
assessment measures, research suggests a wide array of impairments, patterns of impairments, and unclear
trajectories posttransplant. This review provides an abbreviated synthesis of recent research on cognitive
impairments observed in organ-eligible candidates and potential trajectories through posttransplant, current
clinical recommendations regarding integration of assessment into routine clinical transplant practice, as
well as recommendations for future research.
Recent findings
Transplantation may resolve certain disease-contributing factors to cognitive impairments but also introduces
new potential neurocognitive assaults. Recent studies in kidney and lung recipients document continued
impairments in subsets of patients, particularly those identified as frail. For liver candidates, new
assessment measures of hepatic encephalopathy have been developed and preliminarily tested with
potential for translation into routine clinical care. Clinical implications, as well as ethical considerations are
discussed.
Summary
Although guidelines agree that cognitive assessment is an important part of the organ transplantation
process, many questions remain of how to best assess cognition and intervene when cognitive impairment
is identified in transplant populations. Further research should focus on prospective, longitudinal
assessments in transplant-eligible populations through posttransplant.
Keywords
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INTRODUCTION
End-stage organ diseases eligible for solid organ transplantation (SOT, hereafter to refer to heart, kidney,
liver, and lung) are all associated with various neurocognitive assaults and resulting cognitive impairments. The underlying mechanisms contributing to
cognitive impairment are thought to be because of a
complex and dynamic interplay of progressively worsening organ failure, associated comorbidities, and in
some cases, the interventions to treat or maintain the
patient (e.g. dialysis) [1–8]. Although exact mechanisms across organ systems are not yet fully understood, these impairments are associated with negative
effects on patient and their families’ functioning and
patient clinical outcomes including mortality
[9,10 ,11–15]. As a result, national guidelines recommend pretransplant assessment of cognitive functioning [16–18]. However, which instruments to use,
&&

timing of assessments, other considerations in relation to assessment, and how to address cognitive
concerns are left up to the transplant center to determine. As such, this review provides an abbreviated
synthesis of recent empirical research on patterns of
cognitive impairments observed in SOT-eligible candidates and potential trajectories through posttransplant, current clinical recommendations regarding
integration of assessment into routine clinical

a
Transplant Institute, bInternal Medicine, Henry Ford Health, Detroit,
Michigan and cBio-behavioral Medicine, Medical University of South
Carolina, Charleston, South Carolina, USA

Correspondence to Michelle T. Jesse, PhD, FAST, 2799 West Grand
Boulevard, Detroit, MI 48202, USA. E-mail: Mjesse1@hfhs.org
Curr Opin Organ Transplant 2022, 25:000–000
DOI:10.1097/MOT.0000000000001021

1087-2418 Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

www.co-transplantation.com

Copyright © 2022 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

CE: Swati; MOT/27605; Total nos of Pages: 7;

MOT 27605

Psychosocial and ethical issues in organ transplantation

KEY POINTS
 SOT candidates and recipients are at increased risk for
cognitive impairments beyond normal aging, which has
significant implications for access to transplant and
clinical outcomes such as graft loss and mortality.
 Determining whether candidates or recipients have
potential cognitive impairments requires careful
selection, implementation, and interpretation of
instruments/assessment batteries by appropriately
trained and credentialed professionals with adequate
understanding of the broader clinical population.
 Though validated interventions to date are limited,
when cognitive impairments are identified, efforts
should aim to minimize potential neurocognitive
assaults (if possible) and facilitate resources aimed at
supporting patients throughout the transplant process.

transplant practice, as well as recommendations for
future research.

COGNITIVE FUNCTIONING AND
IMPAIRMENT IN SOLID ORGAN
TRANSPLANT POPULATIONS
Cognitive functioning is an umbrella term of the
numerous ways the brain displays differential abilities and interactions between abilities. This
includes memory, attentional capacity, spatial orientation, language skills, and executive functioning
[19]. Detailed explanations of these constructs are
available elsewhere [19,20], though domains frequently discussed in SOT populations are global
(or a composite of overall functioning), memory,
attention, and executive functioning. Evidence of
impairments are broadly categorized as mild, moderate, or severe. Mild cognitive impairment (MCI),
often attributed to normal aging (e.g. occasional
forgetfulness), is defined as impairment greater than
would be expected for the individual’s age but does
not notably or significantly interfere with daily life
[21]. However, as cognitive impairments worsen,
behavioral presentations may indicate that the individual needs more support for routine activities such
as managing finances or, in more severe forms, basic
self-care. In clinical practice, cognitive impairments
is operationalized by scores on different measures,
from brief screeners with cutoff scores (e.g. Montreal
Cognitive Assessment [22 ,23]) to more lengthy
measures of multiple cognitive domains (e.g.
Repeatable Battery of Neuropsychological Status
[24]) to traditional neuropsychological batteries tailored to organ specific concerns [25].
Although SOT candidate populations are at risk
for cognitive impairments, prevalence of global or
&
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domain-specific functioning varies considerably
and are difficult to accurately determine because
of heterogeneity of assessment instruments, psychometric properties of the instruments (including cutoffs), timing of assessments, and inherent variability
in patient selection for referral and evaluation for
transplant. For example, reported cognitive impairments has ranged from 42 [26 ] to 80% [27] in liver
candidate populations and 10 [14] to 55% [28] in
kidney-eligible cohorts. Although the broader endstage organ disease population is a starting point,
patients selected for referral and evaluation for
transplant are likely a healthier subset and, therefore, translating prevalence should be interpreted
cautiously. Regardless, as outlined above, SO- eligible patients are at increased risk for cognitive
impairments and associated negative outcomes
and, therefore, assessment and mitigation of negative effects are recommended.
Although SOT may resolve certain contributors
to cognitive decline or impairment, it also introduces new potential threats including perioperative
and postoperative events (e.g. hypertensive encephalopathy), neurotoxicity of immunosuppressant
medications, infections, electrolyte disturbances,
cerebrovascular disease, and/or normal aging associated with increased lifespan [29–32]. Whether
cognitive functioning improves with organ transplant appears to vary across the organ systems and is
complicated by variable trajectories over time
because of normal aging, new posttransplant neurocognitive assaults, unfortunate selection biases due
to mortality and other attrition, and even may be
dependent upon the research designs implemented
(e.g. cross-sectional versus prospective). Although
cross-sectional comparisons suggest transplant
recipients perform better than transplant candidate
populations on cognitive assessments [33,34], prospective, longitudinal assessments examining cognitive functioning trajectories and associated factors
through posttransplant are overall limited and additional research is needed. However, recent publications in kidney, lung, and liver populations have
provided valuable information. Chu et al. [35]
assessed 665 kidney recipients with the Modified
Mini-Mental Status Examination (3MS) upon admission for transplant and repeated assessments at 3
months, 6 months, 1 year and every year up to
4 years posttransplant (median follow-up 1.5 years).
The findings from this study suggest that cognitive
functioning appeared to improve at 3 months posttransplant, on average; however, functioning was
relatively stable for those identified as nonfrail pretransplant, whereas those who were identified as
frail had significant declines [35]. Although this
study provided much needed longitudinal data on
&
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global cognitive trajectories in kidney transplant
recipients, there are still questions of domain-specific
trajectories. Smith et al. [25,36] conducted the most
comprehensive prospective neuropsychological
assessments to date of lung transplant candidates
through 6 months posttransplant. They reported that
performance across 49 lung recipients was generally
within normative ranges at 6 months posttransplant
but 20% of transplant recipients showed impairment
in at least one cognitive domain, most commonly the
Animal Naming Test, which measures semantic fluency. Importantly, in final models, better performance on tests of processing speed and executive
functioning were associated with better survival
[25]. Per our knowledge, for heart transplant recipients, there appears to be limited recent prospective
research examining how or whether cognitive functioning changes posttransplant (Cupples and Stilley
[37] provide a thorough overview of publications
€ rker et al.
published prior to 2005). However, Bu
[38,39] conducted a cross-sectional assessment of
heart transplant recipients (n ¼ 37, average of 20 years
posttransplant) and reported nearly 40% displayed
evidence of cognitive impairments in at least
one domain (i.e. processing speed, executive functioning, memory, and language processing). Liver
populations and cognitive impairments have arguably received more empirical attention because
of the occurrence of hepatic encephalopathy
[11,12,40,41]. However, groups have conducted preliver-to-postliver transplant assessment of cognitive
impairments, but as Albhaisi and Bajaj [27] conclude,
there are contradictory findings across studies in liver
recipient populations. In short, there is not robust,
clear evidence of beneficial effects of transplantation
on cognitive impairments.

CLINICAL, ETHICAL, AND CULTURAL
CONSIDERATIONS IN ASSESSMENT AND
INTERVENTION
There are a multitude of factors requiring careful
consideration in the appropriate and ethical implementation of cognitive testing in complex, chronic
disease patient populations. This includes, but is not
limited to, the training and qualifications of the
assessor; appropriate test selection for the population
including relevant domains of assessment and corresponding psychometrics; appropriate adjustment for
confounding factors to account for real-world clinical
settings (e.g. inpatient versus outpatient); accurate
and appropriate scoring and interpretation and translation and application of findings. National guidelines on assessment and evaluation outline that
individuals selecting the test and/or assessing should
have adequate education and training in the above

outlined for appropriate and ethical practice [42]. In
the case of cognitive assessment in SOT, this not only
includes selecting measures that have shown validity
in SOT or similar populations (i.e. patients with endstage organ disease) but also understanding the limitations of using the selected measure in SOT patients
(e.g. length of assessment in patients with medical
complications). Furthermore, some assessment measures, such as the MoCA, require their own certification to ensure validity of use and application of
findings [43]. Failing to achieve competency in cognitive assessment may not just compromise the quality of clinical data but may constitute unethical
practice and contribute to inequities in patient care,
SOT candidate selection, and outcomes.
In addition to test selection and use, competency to conduct cognitive assessment includes
interpretation, integration, and application of findings, which necessitates a comprehensive evaluation of the patient. Comprehensive evaluation
should include patient’s medical and psychiatric
history and current psychosocial context, in addition to assessment of current cognitive functioning
(e.g. using a screening measure) and other aspects of
the patient’s presentation that can impact performance on cognitive screeners and neurocognitive
assessments. For example, depressive symptoms
are associated with reduced performance across several domains of cognitive functioning [44], and are
prevalent in pretransplant populations [45]. Therefore, assessing for depressive symptoms is recommended to determine whether depressive symptoms
are inflating cognitive impairment levels. However,
similar considerations for test selection and assessor
expertise are relevant as many depressive symptom
assessments include somatic elements, which can
inflate depressive symptoms in chronic disease populations and potentially lead to misinterpretation.
Other measures have poor psychometric properties,
but as they are easily accessible and free for use, they
have been rampant. For example, the Hospital Anxiety and Depression Scale (HADS) is frequently used
as a proxy for anxiety and/or depression severity;
however, in addition to conflating disease-specific
medical symptoms with depressive symptoms, the
HADS has poor psychometric properties and validity
studies suggest it is in fact a unitary measure of
distress rather than a screener for either anxiety or
depressive symptoms [46–49].
Similarly, history of substance use, as well as
current use, may relate to cognitive impairment.
Chronic alcohol use has an impact on several
dimensions of cognitive functioning, and women
may experience more alcohol-related cognitive
impairments [50]. This may be of particular concern
given the rise of alcohol misuse and death rates from
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liver disease in women over the last several years,
which has perhaps amplified an additional disparity
in liver transplantation [51]. History of tobacco use
has also been associated with cognitive impairment
in kidney transplant candidates [28], which is reflective of patterns of cognitive impairment in the
population of tobacco smokers broadly [52].
Another factor to consider in assessing cognition
is increasing age and normative age-related cognitive
changes, which may be of particular concern given
the generally aging population in the United States
and increasing age of transplant recipients [53,54].
Recent studies have also found that the prevalence of
global cognitive impairment and cognitive impairment burden steadily increased with age in kidney
transplant populations [55 ]. Other factors, such as
the assessment itself may also be relevant to interpretation and application of results, such as the setting of
the evaluation (inpatient versus outpatient), which
may introduce other confounding factors such as
recent medication administration or frequent interruptions during evaluation. These may impact attention to and concentration on the evaluation, and
influence patient effort on cognitive measures, both
of which then could lead to misrepresentation of the
patient’s true cognitive functioning.
&

Comment on ethics and equity
Race/ethnicity has also been associated with cognitive impairment in SOT patients [28]. This may be in
no small part because of not only the effects of
systemic racism but also the inherent biases in neuropsychological testing [56,57]. However, several
cognitive screening measures have been validated
in various populations [56] and the MoCA, in particular has 86 culturally different versions [58].
Maintaining cultural competence is essential in
the competent assessment in diverse, underrepresented, and vulnerable populations [42,59].
Cognitive impairment itself is often a source of
inequity in the transplant process. Patients with
cognitive impairment have been shown to take
longer to get to listing and were less likely to be
listed for transplant and stay on the list [28]. Shrestha et al. [60 ,61 ] have conducted interviews with
both expert providers and kidney transplant candidates themselves, generally finding that both populations want to maintain equity and utility in the
transplant process, and that frailty and cognition
factors should be used consistently in transplant
selection. The authors have called for the development of clear ethical guidelines for the use of cognitive function in transplant decision-making
[61 ]; however, this also will require ethical/competent use of cognitive assessment data. It is also
&&
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worth noting that the OPTN Ethics Committee has
already recommended the ethical use of nonmedical
criteria (e.g. life expectancy, social support, psychosocial factors) by using the most current evidence
available and balancing the ethical principles of
utility, justice, and respect for persons [62].

CUTTING EDGE ASSESSMENT AND
PURSUIT OF THE ELUSIVE GOLD
STANDARD
Due to numerous reasons, including the breadth of
mechanisms, complex contributing factors, a multitude of available and routinely used assessment
measures [63], and a dearth of transplant norms
for common measures, finding a gold standard
assessment for SOT candidates and recipients across
organ types may be unlikely in the near future.
Selection of appropriate measures requires extensive
consideration, outlined above, but there have been
some exciting and novel approaches to detecting
changes in cognitive presentations. For example,
the EncephalApp is a Stroop test, a measure of
selective attention and processing speed, with a
publicly available iOS app [64]. The app, developed
by Bajaj et al. [40,65], has shown good sensitivity
and specificity in detecting minimal hepatic encephalopathy compared with established measures.
Other recent work has piloted examining National
Language Processing from patient communications
within their electronic health records in relation to
transplant outcomes [66]. Although significantly
more work is needed in validating these approaches,
they do provide innovative spaces for future
research into identifying those at risk for cognitive
impairments and associated negative outcomes.

CURRENT CLINICAL MANAGEMENT OF
COGNITIVE IMPAIRMENT
As outlined above, all SOT candidates should
undergo routine cognitive assessment and re-assessment as needed based upon clinician, patient, and/
or care partner concern. Once cognitive impairment
has been identified, the natural next steps are efforts
towards mitigating long-term negative effects of
current medical contributors (e.g. lactulose in liver
failure) and implementing behavioral interventions. However, in some cases, the neurocognitive
assault is central to the patient’s treatment (e.g.
chronic hemodialysis) and, therefore, medical mitigation may not be possible/feasible. However,
behavioral interventions are common, and though
not well studied in SOT populations, preliminary
data and evidence from other chronic disease
patient populations suggest protective effects. A
Volume 25  Number 00  Month 2022
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common strategy of SOT clinical providers is mobilization of patient social supports so that the
support system is aware of the patient cognitive
impairment and can help when and where needed
[60 ,61 ,67 ,68–70]. Preliminary data suggest this
type of strategy may reduce hospital readmissions in
the preheart transplant period [67 ], but fully-powered controlled trials are needed to confirm.
Additional behavioral interventions showing
promise for preserving cognitive functioning for
end-stage organ disease populations include physical activity/exercise and cognitive rehabilitation or
training [71]. Song et al. [72] conducted a randomized controlled trial of computerized cognitive training in lung transplant recipients over age 55 years.
Those that received the intervention (as compared
with the passive controls) showed improvements on
specific attention and language tasks. Despite having a small sample (intervention n ¼ 23, control
n ¼ 23), this study provided valuable preliminary
data for interventions aimed at preserving cognitive
functioning in the posttransplant period.
&&
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FUTURE DIRECTIONS/
RECOMMENDATIONS
There is a significant need for prospective, longitudinal assessments in transplant-eligible populations
through posttransplant. Across all SOT population,
recent research has focused on the relationship
between pretransplant frailty phenotypes that
included assessments of cognitive functioning, on
outcomes including listing outcomes and posttransplant hospitalizations and mortality [9,26 ,28,73–
76,77 ,78,79]. As these patients progress and further
follow-up is conducted, additional data may emerge
on effects of cognitive impairments over time. As
cognitive impairment and frailty are closely related,
interventions targeting frailty in other chronic disease populations show beneficial effects on both
frailty and cognitive functioning.
&

&

CONCLUSION
Cognitive impairments in end-stage organ diseases
are prevalent with different contributing factors
across organ systems. Although organ transplantation generally improves cognition posttransplant,
there are subsets of patients at risk for further cognitive decline. Early identification of cognitive
impairments and associated neurocognitive assaults
permits both for earlier medical intervention to
attempt to preserve cognitive functioning but also
time to ensure adequate resources for the patient to
foster their safety and well-being.
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